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OBJECTIVE—Phosphoinositide 3-kinase enhancer A (PIKE-A)
is a proto-oncogene that promotes tumor growth and transfor-
mation by enhancing Akt activity. However, the physiological
functions of PIKE-A in peripheral tissues are unknown. Here, we
describe the effect of PIKE deletion in mice and explore the role
of PIKE-A in obesity development.
RESEARCH DESIGN AND METHODS—Whole-body PIKE
knockout mice were generated and subjected to high-fat–diet
feeding for 20 weeks. The glucose tolerance, tissue-speciﬁc
insulin sensitivity, adipocyte differentiation, and lipid oxidation
status were determined. The molecular mechanism of PIKE in
the insulin signaling pathway was also studied.
RESULTS—We show that PIKE-A regulates obesity develop-
ment by modulating AMP-activated protein kinase (AMPK) phos-
phorylation. PIKE-A is important for insulin to suppress AMPK
phosphorylation. The expression of PIKE-A is markedly in-
creased in adipose tissue of obese mice, whereas depletion of
PIKE-A inhibits adipocyte differentiation. PIKE knockout mice
exhibit a prominent phenotype of lipoatrophy and are resistant to
high-fat diet–induced obesity, liver steatosis, and diabetes. PIKE
knockout mice also have augmented lipid oxidation, which is
accompanied by enhanced AMPK phosphorylation in both mus-
cle and adipose tissue. Moreover, insulin sensitivity is improved
in PIKE-A–deﬁcient muscle and fat, thus protecting the animals
from diet-induced diabetes.
CONCLUSIONS—Our results suggest that PIKE-A is implicated
in obesity and associated diabetes development by negatively
regulating AMPK activity. Diabetes 59:883–893, 2010
O
besity is a result of imbalanced energy intake
and expenditure in which the accumulation of
excessive fat causes disorders such as type 2
diabetes, atherosclerosis, and dyslipidemia (1).
Because of its increasing prevalence in most of the world,
obesity has became a major health problem (2). Although
genetic linkage analysis has successfully mapped potential
loci in human genome for adiposity development (3),
identifying all genetic variants that contribute to differ-
ences in body weight is still one of the major goals to fully
understand the mechanism of obesity progression. Recent
studies using genome-wide linkage scan revealed human
chromosome trait 12q14.1, where the phosphatidylinositol
3-kinase (PI 3-kinase) enhancer (PIKE) gene CENTG1
locates, has a strong correlation with serum lipid level and
energy intake (4,5), suggesting PIKE may be a potential
factor in regulating body weight.
PIKEs are a family of GTPases that directly interact with
PI 3-kinase and Akt and enhance their kinase activities
(6–8). The family contains three members: PIKE-L,
PIKE-S, and PIKE-A, which is generated from alternative
splicing of the CENTG1 gene. Whereas PIKE-S and -L are
brain speciﬁc, PIKE-A is widely expressed, such that its
mRNA could be detected in brain, heart, liver, muscle,
spleen, thymus, and small intestine (9,10). The mode of
action of PIKE is isoform speciﬁc in different cell types.
PIKE-L couples to receptors such as netrin receptor
(UNC5B) and metabotropic glutamate receptors I (mGluR-I)
and links the activated receptor to PI 3-kinase pathway in
neurons (11,12). PIKE-S localizes in nucleus and executes
the protective effects of nerve growth factor by activating
the nuclear PI 3-kinase cascade (8). PIKE-A, on the other
hand, substantiates the kinase activity of Akt in glioblas-
tomas and is involved in cancer invasion activity (6,13,14).
However, the role of PIKE-A in peripheral tissues remains
unknown.
In many cases, insulin resistance is the major associated
pathologic condition of obesity. However, the molecular
mechanism of this obesity-induced disorder remains am-
biguous. It has been proposed that lipotoxicity is one of
the candidates to explain the role of excess lipid storage in
insulin resistance onset. Accumulation of excess cellular
lipid changes the lipid metabolism, enhances oxidative
stress, and disrupts endoplasmic reticulum homeostasis
(15). Increasing cellular lipid oxidation by pharmacologic
interventions in obese subjects thus represents a potential
therapeutic regimen to mitigate their diabetic complica-
tions. In this regard, AMP-activated protein kinase (AMPK)
is one of the targets. AMPK is the master sensor for energy
status and is responsible for metabolic homeostasis (16).
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genic gene expression and glucose production, increasing
fatty acid oxidation, and enhancing glucose uptake. There-
fore, AMPK activators such as AICAR and metformin are
effective agents in relieving the obesity-induced insulin
resistance in both laboratory and clinical tests (17).
To examine the role of PIKE in obesity, we developed
the whole-body PIKE knockout (PIKE
/) mice with
ablation of all PIKE isoforms. Here we report that PIKE-A
is implicated in adipocyte differentiation and obesity de-
velopment. PIKE knockout elicits lipoatrophy and in-
creased insulin sensitivity by enhancing AMPK activity,
leading to resistance against high-fat diet (HFD)-induced
obesity and diabetes.
RESEARCH DESIGN AND METHODS
Generation of knockout animals and genotyping. Heterozygous PIKE
/
C57BL/6 mice with a targeted deletion of exons 3–6 of CENTG1 were
generated under contract by Ozgene (Bentley DC, Australia). Genotyping was
performed by PCR using genomic DNA isolated from the tail tip. PCR was
performed using a combination of primers D (5ACAGGATCAGTGCAT-
CATCTC3) ,H( 5 CTGCCCAGCTACAGGAGTAG3) ,A( 5 TCAGTTGACTG-
GAAGCTCTG3), and C (5CCAGAGCCTATCTATGCCTAG3).
Immunoprecipitation and Western blotting. Tissue extracts were pre-
pared by homogenizing the tissues in buffer as reported (18). Immunoprecipi-
tation was performed as described (18). Antibodies used in the Western blot
analysis were obtained from Santa Cruz Biotechnology (insulin receptor, Akt)
and Cell Signaling Technology (anti–phosphor-Thr
308 of Akt, anti–phosphor-
Thr
172 of AMPK, anti–phosphor-Ser
79 of acetyl-CoA carboxylase [ACC], anti-
AMPK, and anti-ACC).
Southern blot analysis. Southern blot analysis using mouse tail genomic
DNA was performed as reported (19).
Analytic procedures. All animal experiments were performed according to
the care of experimental animal guidelines from Emory University. Twelve-
week-old female mice were fed with chow or HFD (Research Diets) for 20
weeks. Blood glucose level was measured by ACCU-CHEK Advantage Blood
Glucose Meter (F. Hoffmann-La Roche, Basel, Switzerland). Serum insulin was
measured by ELISA (Crystal Chem). Serum triglyceride level was measured by
Serum Triglyceride Determination Kit (Sigma-Aldrich). Serum tumor necrosis
factor- (TNF-) was measured by ELISA (BD Biosciences). Glucose toler-
ance test (GTT) was performed on mice after peritoneal injection of D-glucose
(2 g/kg body wt).
In vivo insulin stimulation. Animals (16 h fasting) were anesthetized by
intraperitoneal administration of sodium pentobarbital (50 mg/kg body wt).
Saline or 5 units human insulin (Eli Lilly) was injected through inferior vena
cava. After 5 min, liver, hind limb muscles, and inguinal fat were removed and
immediately frozen in liquid nitrogen.
PI 3-kinase assay. In vitro PI 3-kinase assay was performed using anti-p110
(Santa Cruz Biotechnology) as described previously (8).
RT-PCR. Total RNA from various tissues was prepared by Trizol Isolation
Reagent (Invitrogen). First-strand cDNA from total RNA was synthesized using
Superscript III reverse transcriptase (Invitrogen) and Oligo-dT17 as primer.
Ampliﬁcation of preadipocyte factor 1 (Pref-1), adipocyte protein 2 (aP2),
peroxisome proliferator–activated receptor- (PPAR), and C BP was per-
formed using primers mPref1-F (5-GACCCACCCTGTGACCCC-3), mPref1-R
(5-CAGGCAGCTCGTGCACCCC-3); maP2-F (5-CAAAATGTGTGATGCCTTT
GTG-3), maP2-R (5-CTCTTCCTTTGGCTCATGCC-3); mPPARg2-F (5-ATGCT
GTTATGGGTGAAACT-3), mPPARg2-R (5-CTTGGAGCTTCAGGTCATATTT
GTA-3); and mC BPa-F (5-ATCCCAGAGGGACTGGAGTT-3), mC BPa-R (5-
AAGTCTTAGCCGGAGGAAGC-3). Expression of PIKE-A was determined using
primers D and H as described above. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was also ampliﬁed as internal standard using primers 5-CGCATCTT
CTTGTGCAGTGCC-3 (forward) and 5-GGCCTTGACTGTGCCGTTGAATTT-3
(reverse).
In vitro
3H-2-deoxyglucose uptake.
3H-2-deoxyglucose uptake in soleus
muscle and inguinal fat pad was performed in the presence or absence of
human insulin (Eli Lilly) as reported (20).
Fatty acid oxidation assay. Fatty acid oxidation was measured by deter-
mining the production of
3H2O from [9,10-
3H]-palmitate as reported (21).
Hyperinsulinemic-euglycemic clamp and metabolic cage studies. Meta-
bolic cage studies and in vivo glucose metabolisms including glucose infusion
rate, glucose turnover rate, and glycogen synthesis were determined by
hyperinsulinemic-euglycemic clamp as reported (22,23).
Statistical analysis. Results were considered signiﬁcant when P  0.05.
Statistical analysis was performed using either Student t test, one-way
ANOVA, or two-way ANOVA followed by Tukey multiple comparison test or
Bonferroni post-tests using the computer program GraphPad Prism (Graph-
Pad Software).
Detailed experimental procedures are in the supplementary methods (http://
diabetes.diabetesjournals.org/cgi/content/full/db09-1404/DC1).
RESULTS
Generation of PIKE knockout mice. As a pioneer study
on the physiological role of PIKE in obesity development,
we generated whole-body PIKE
/ mice with targeted
disruption in the CENTG1 locus using the LoxP/Cre sys-
tem. We ﬁrst created a transgenic line with PIKE
ﬂox/
allele by inserting two loxP sites into the introns ﬂanking
exons 3 and 6 (Fig. 1A). PIKE
ﬂox/ mice were then bred
with transgenic mice expressing Cre recombinase in all
tissues. Deletion of exons 3–6 results in removal of
GTPase domain and introduces a frameshift mutation that
creates a new stop codon, producing truncated PIKE
proteins for all isoforms. Heterozygous mating generated
newborn pups at expected Mendelian frequency that ap-
peared indistinguishable from the wild-type littermates,
suggesting that PIKE was dispensable for embryonic de-
velopment. Southern blot analysis showed exons 3–6 of
the CENTG1 gene were effectively excised (Fig. 1B),
which was further supported by PCR analysis (Fig. 1C).
Immunoblotting analysis using antibody speciﬁc to the
COOH-terminal of PIKE-A and RT-PCR conﬁrmed the
ablation of PIKE-A expression in various tissues (Fig. 1D
and E). PIKE
/ mice are viable and fertile. However, a
signiﬁcant reduction of white adipose tissues (WATs) was
detected in the PIKE
/ mice, whereas no noticeable
difference was found in other peripheral tissues (Fig. 1E).
PIKE
/ mice are resistant to diet-induced obesity.
When fed a chow diet, the body weight of female PIKE
/
mice was slightly, but signiﬁcantly, lower at 8 weeks old
compared with wild-type mice (17.29  0.27 vs. 16.33 
0.29 g, P  0.05, n  7, Student t test). The difference was
more prominent in mice fed with HFD (55% of calories
derived from fat). After HFD feeding for 14 weeks, obesity
developed in wild-type but not in PIKE
/ animals (Fig.
2A). Daily food intake of PIKE
/ mice fed a chow diet
was normal, but the amount of food intake in PIKE
/
mice was substantially less than that in the control fed
HFD (Fig. 2B). Increased body weight was associated with
a drastic gain of inguinal WAT weight in wild-type but not
in PIKE
/ mice (312% in wild-type vs. 46.5% in knockout)
(Fig. 2C). The adipocytes in PIKE
/ mice were also
smaller in both feeding conditions (Fig. 2D and E). More-
over, circulating leptin and TNF- concentrations were
lower in PIKE
/ mice (Fig. 2F and G). Expression of
PIKE-A was greatly enhanced in the WAT and muscle of
mice fed with HFD and the genetically obese (ob/ob) mice
(Fig. 2H, ﬁrst and ﬁfth panels). In contrast, no noticeable
alternation of hepatic PIKE expression was detected
among all the tested groups (Fig. 2H, third panel), sug-
gesting a tissue-speciﬁc function of PIKE-A in obesity
development.
PIKE is essential for adipocyte differentiation. Under
chow diet feeding conditions, expressions of mature adi-
pocyte markers aP2 and the master regulators of adipo-
cyte differentiation, PPAR and C/EBP (24,25), were
reduced in PIKE
/ WAT (Fig. 3A). However, no signiﬁ-
cant difference was found in preadipocyte marker Pref-1
between wild-type and mutant. Comparable increment of
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FIG. 1. Targeted disruption of PIKE. A: Schematic representation of mouse PIKE (top), the targeting vector (middle), and the targeted gene
region (bottom). The locations of loxP sites were marked as solid triangles and of FRT sites, as solid bars. B: Southern blot analysis of progeny
produced from heterozygote mating. Genomic DNA was isolated from mouse tail and was digested with NheI and probed with fragment A as
indicated. The 8.5-kb band represents the wild-type allele and the 6-kb fragment corresponds to the knockout allele. C: PCR screening of mice
from heterozygote mating. Genomic DNA isolated from wild-type (/), heterozygous (/), and knockout (/) mice tail was used in PCR
screening. The locations of primers used in the reactions were indicated in A. D: RT-PCR screening of PIKE expression in different tissues.
Complementary DNA was synthesized from RNA extracted from various tissues as indicated. Primers D and H as shown in A were used in PCR
(upper panel). Expression of GAPDH was examined as the internal control (lower panel). E: Western blot analysis of PIKE-A. Proteins extracts
of different tissues from wild-type (/) and knockout (/) mice (3 months old) were prepared, and the expression of PIKE-A was detected
using speciﬁc antibody against the COOH-terminal of human PIKE-A (top panel). The amount of tubulin in each sample was examined to
demonstrate equal loading (bottom panel). Representative result of three mice from each genotype was shown. F: Weight of heart, spleen,
pancreas, kidney, and inguinal WAT in 3-month-old mice. The weight was normalized with the total body weight and was expressed as means 
SEM (n  5). Signiﬁcant reduction of WAT weight was observed in PIKE
/ mice (***P < 0.001, Student t test).
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HFD, suggesting the proliferation of preadipocyte was
similar in both genotypes (Fig. 3A). However, subsequent
adipocyte differentiation was impaired in PIKE
/ mice as
the expression of aP2, PPAR, and C/EBP was greatly
reduced.
Next, we sought to determine whether the deletion of
PIKE-A per se is sufﬁcient to prevent adipogenesis in vitro.
Whereas mouse embryonic ﬁbroblasts (MEFs) from wild-
type mice differentiated into adipocytes, as evident by the
accumulation of lipid droplets within the cells, PIKE
/
MEFs failed to fully differentiate under the same condition
(Fig. 3B). A signiﬁcantly lower amount of oil red O staining
was found in PIKE
/ MEFs after induction (Fig. 3C).
Moreover, expression of mature adipocyte markers aP2,
C/EBP, and PPAR was lower in PIKE
/ MEFs after
differentiation (Fig. 3D), which was consistent with the
ﬁndings in WAT. These results suggest lipoatrophy is a
direct consequence of PIKE-A depletion in WAT, which
may explain the reduced adiposity of mutant mice.
PIKE knockout mice are protected from diet-induced
hyperglycemia by enhanced systemic insulin sensitivity.
Adipocyte dysfunction is one of the major factors that
causes insulin resistance (26); therefore, we examined the
effects of diet-induced diabetes in PIKE
/ mice. In HFD
treatment, hyperglycemia was observed in both genotypes
when the animals were fed. Hyperglycemia was sustained
in fasted wild-type animals but not in PIKE
/ mice (Fig.
4A). Moreover, PIKE
/ mice on HFD showed improved
glucose tolerance during the GTT (Fig. 4B). A lower
amount of insulin was also secreted in PIKE
/ mice
treated with HFD during the GTT (supplementary Fig. 1A).
In parallel, less circulating insulin was detected in
PIKE
/ mice in both feeding conditions (Fig. 4C), sug-
gesting a higher insulin sensitivity. This notion was further
supported by higher glucose infusion rate (Fig. 4D), whole-
body glucose turnover (supplementary Fig. 1B), and gly-
cogen synthesis (supplementary Fig. 1C)i nPIKE
/ mice
during the hyperinsulinemic-euglycemic clamp studies.
Hepatic insulin resistance was also alleviated in PIKE
/
mice fed with HFD (supplementary Fig. 1D), which pro-
vides further explanation to the relieved diabetic pheno-
type in PIKE
/ mice because hepatic insulin resistance is
associated with diabetes (27). We also examined the
insulin-stimulated signaling in tissues responsible for glu-
cose utilization to reveal the molecular basis of the en-
hanced insulin sensitivity in PIKE
/ mice. In mice fed a
normal chow diet, comparable tyrosine phosphorylation
of insulin receptor occurred in WAT and muscle of both
genotypes after in vivo insulin injection (Fig. 4E, ﬁrst
panel). However, insulin provoked higher insulin sub-
strate-1 (IRS-1) phosphorylation, PI 3-kinase activity, and
Akt phosphorylation in PIKE
/ WAT and muscle (Fig. 4E,
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FIG. 2. PIKE knockout mice are resistant to diet-induced obesity. A:
Growth curve of 3-month-old wild-type (/) and PIKE knockout
(/) mice fed with HFD. Body weight was measured weekly and
expressed as mean  SEM (n  7–10; **P < 0.01, ***P < 0.001, two-way
ANOVA). B: Food intake by wild-type (/) and knockout (/) mice
fed with chow or HFD was measured in a 3-day period. Results were
expressed as mean  SEM (**P < 0.01 vs. the same genotype; c: P <
0.001 vs. the same diet; one-way ANOVA, n  4). C: Weight of inguinal
WAT from wild-type (/) and PIKE knockout (/) mice (8–9
months old, n  5) that have been fed with chow diet or HFD for 20
weeks. Data were expressed as mean  SEM (***P < 0.001 vs. the
same genotype, b: P < 0.01, c: P < 0.001 vs. the same diet treatment;
one-way ANOVA). D: Pictures of hematoxylin-eosin (H&E) staining of
inguinal WAT sections from wild-type (/) and PIKE-null (/)
animals (8–9 months old) that have been fed with chow diet or HFD for
20 weeks. Representative results of three different mice from each
genotype were shown. Scale bar represents 50 m. E: Quantiﬁcation of
inguinal WAT cell area from wild-type (/) and PIKE-null (/)
animals (8–9 months old) that have been fed with chow diet or HFD
for 20 weeks (n  4). Results were expressed as mean  SEM
(***P < 0.001 vs. the same genotype, b: P < 0.01 vs. the same diet
treatment; one-way ANOVA). F: Circulating leptin concentration of
wild-type (/) and PIKE knockout (/) mice (8–9 months old) that
have been fed with chow or HFD for 20 weeks. Results were expressed
as mean  SEM (n  4; *P < 0.05, ***P < 0.001 vs. the same genotype;
a: P < 0.05, b: P < 0.01 vs. the same diet treatment; one-way ANOVA).
G: Circulating TNF- concentration of wild-type (/) and PIKE
knockout (/) mice (8–9 months old) that have been fed with chow or
HFD for 20 weeks. Results were expressed as mean  SEM (n  4; *P <
0.05, ***P < 0.001 vs. the same genotype; c: P < 0.01 vs. the same diet
treatment; one-way ANOVA). H: Elevated PIKE-A expression in the
WAT and muscle of diet-induced or genetically obese mice. RNA from
WAT, liver, and muscle of ob/ob mice or normal mice (8–9 months old)
that have been fed with chow diet or HFD was extracted and reverse
transcripted. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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insulin hypersensitivity was not detected in PIKE
/ liver
(data not shown). Consistent with higher Akt phosphory-
lation in WAT and muscle, in vitro
3H-2-deoxyglucose
uptake under insulin stimulation was signiﬁcantly aug-
mented in PIKE
/ muscle and WAT (Fig. 4F). Together,
our data suggest that PIKE
/ muscle and WAT are
hypersensitive to insulin stimulation, leading to higher
glucose uptake, thus protecting the mice from hyperglyce-
mia during HFD treatment.
PIKE-A is an Akt upstream effector, which binds Akt and
enhances its kinase activity in glioblastomas (6,13). It is
thus anticipated that PIKE
/ mice would display diabetic
phenotypes as deletion of Akt2 in mice showed impaired
glucose tolerance (28). To our surprise, blood glucose
level is normal in PIKE
/ mice. Because Akt1
/ or
Akt3
/ mice have no obvious defect in glucose homeosta-
sis, the normoglycemic condition in PIKE
/ mice could
be explained if PIKE-A associates selectively with Akt1
and Akt3 rather than Akt2. As predicted, PIKE-A preferen-
tially bound both Akt1 and Akt3 (supplementary Fig. 2A),
suggesting that only Akt1 and Akt3 activities may be
altered in PIKE
/ tissues. Concurrent with this notion,
the brain mass of PIKE
/ mice was smaller than the
control mice (supplementary Fig. 2B), a phenotype that is
speciﬁcally observed in Akt3-null animals (29).
Lipid oxidation is enhanced in PIKE
/ mice. Animal
models with lipoatrophy often associate with hyperlipid-
emia and ectopic lipid accumulation (30). However, signif-
icant changes in neither circulating triglyceride (Fig. 5A)
nor ectopic lipid depositions in liver (Fig. 5B) were seen in
the PIKE
/ mice, suggesting the excessively absorbed
lipid during HFD feeding in PIKE-null animals may be
metabolized rather than deposited as storage. To test this
possibility, we ﬁrst monitored the frequency of animal
movements using open-ﬁeld locomotor assay (31).
Whereas the activity in wild-type mice decreased when
they adapted to the test cage, physical movement of
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FIG. 3. PIKE is essential for adipocyte differentiation A: Impaired adipose gene expression in PIKE-null WAT. RNA from inguinal WAT of
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control of the same genotype; c: P < 0.001 vs. different genotype under the same treatment; one-way ANOVA, n  3). D: Impaired adipose gene
expression in PIKE-null MEFs. RNA from MEFs of wild-type (/) and knockout (/) mice before (day 0) and after (day 8) induced adipocyte
differentiation. Expression of mature adipocyte marker aP2 and transcription factors PPAR and C/EBP was normalized to GAPDH. Results
were expressed as fold induction against the corresponding expression level in day-0 wild-type MEFs (n  3, **P < 0.01; ***P < 0.001, Student
t test). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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/ mice remained substantially higher throughout
the experiment in both diet conditions (Fig. 5C). We also
examined the metabolic rate using metabolic cages (23).
Respiratory exchange ratio was lower in PIKE
/ animals
in both diet treatments, suggesting that mutant mice have
a higher fatty acid catabolism (Fig. 5D). This suggested
high lipid oxidation was further supported by the high
phosphorylation level of AMPK and ACC in PIKE
/
muscle, brown adipose tissue (BAT), and WAT. AMPK
phosphorylation was reduced after HFD feeding in wild-
type BAT and WAT. However, AMPK in PIKE
/ WAT
remained highly phosphorylated in both feeding groups
(Fig. 5E, ﬁrst and tenth panels). In parallel, phosphoryla-
tion of ACC in PIKE
/ BAT and WAT was higher than the
control group (Fig. 5E, third, fourth, and 12th panels).
Whereas AMPK expression in WAT remained unchanged
after HFD feeding, AMPK in BAT was greatly reduced in
both genotypes (Fig. 5E, second and 11th panels). Expres-
sion of ACC was reduced after HFD treatment in both
wild-type and PIKE
/ BAT and WAT (Fig. 5E, ﬁfth and
13th panels). Interestingly, PIKE
/ BAT has higher ACC
expression (Fig. 5E, 13th panel). Similar phosphorylation
pattern occurred in both AMPK and ACC in PIKE
/
muscle (Fig. 5E, sixth and eighth panels) with unchanged
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FIG. 4. PIKE knockout mice are protected from diet-induced hyperglycemia by enhanced systemic insulin sensitivity. A: Blood glucose level in fed
and fasting (16 h) wild-type (/) and PIKE knockout (/) mice (8–9 months old) that have been fed with chow or HFD for 20 weeks. Results
were expressed as mean  SEM (*P < 0.05; **P < 0.01 vs. the same genotype treated with different diets; a: P < 0.05 vs. different genotypes
treated with the same diet under fasting condition; c: P < 0.001 vs. fed and fasted PIKE
/ mice treated with chow diet; one-way ANOVA, n  4–7).
B: Glucose tolerance test in wild-type (/) and PIKE knockout (/) mice (8–9 months old) that have been fed with HFD for 20 weeks (8–9
months old) after overnight fasting. Blood glucose level was monitored at different time intervals after intraperitoneal injection of glucose (2
g/kg). Results were expressed as mean  SEM (n  7; **P < 0.01; ***P < 0.05 vs. the same genotype; b: P < 0.01, c: P < 0.001 vs. the same diet;
two-way ANOVA). C: Circulating insulin concentration of wild-type (/) and knockout (/) mice (8–9 months old) that have been fed with
chow diet or HFD for 20 weeks (n  4). Results were expressed as mean  SEM (*P < 0.05, **P < 0.01 vs. the same genotype; b: P < 0.01 vs. the
same diet; one-way ANOVA). D: Glucose infusion rate in wild-type (/) and knockout (/) mice (8–9 months old) that have been fed with chow
diet or HFD for 20 weeks during hyperinsulinemic-euglycemic clamp experiment. Results were expressed as mean  SEM (n  9; *P < 0.05, ***P <
0.01 vs. the same diet; c: P < 0.001 vs. the same genotype; one-way ANOVA). E: Enhanced insulin signaling in fasted 3-month-old wild-type (/)
and PIKE-null (/) mice fed with chow diet. Mice were administered saline () or 5 units human insulin () via the inferior vena cava. After
5 min, inguinal WAT and skeletal muscle were isolated and frozen in liquid nitrogen. The phosphorylation of insulin receptor (ﬁrst panel), IRS-1
(third panel), and Akt (Thr
308 and Ser
473)( sixth and seventh panels) was determined using speciﬁc antibodies as indicated. PI 3-kinases in the
tissues were precipitated using anti-p110 antibody and their activities were assayed (ﬁfth panel). The expression of total insulin receptor (second
panel), IRS-1 (fourth panel), and Akt (eighth panel) was determined to show equal loading. Representative results from three mice of each genotype
were shown. F: Insulin elicits higher glucose uptake in fat and muscle of PIKE-null mice. Soleus muscle and inguinal WAT excised from 3- to 5-month-old
wild-type (/)o rPIKE knockout (/) mice were used in determining the
3H-2-deoxyglucose uptake in the presence of 10 mU/ml human insulin.
Results were presented as mean  SEM (n  3; *P < 0.05 vs. the same genotype; a: P < 0.05 vs. the same treatment, one-way ANOVA).
PIKE AND OBESITY
888 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgprotein levels (32) (Fig. 5E, seventh and ninth panels). In
contrast, no signiﬁcant changes in hypothalamic AMPK
and ACC phosphorylation were found in PIKE
/ animals
in both feeding conditions (supplementary Fig. 3A). More-
over, AMPK and ACC phosphorylation was not enhanced
in PIKE
/ MEFs (supplementary Fig. 3B). These results
suggest a tissue-speciﬁc effect of PIKE-A in modulating
AMPK and ACC activity. We have also performed the fatty
acid oxidation assay in cultured PIKE
/ muscle cells and
hepatocytes. In agreement with the immunoblotting anal-
ysis in Fig. 5E, an elevated palmitate oxidation rate was
detected in PIKE
/ muscle cells but not hepatocytes
(Fig. 5F).
Therefore, the high physical activity of PIKE
/ mice
and enhanced lipid oxidation in BAT, WAT, and muscle
may account for their lean phenotype during HFD
feeding. The higher AMPK phosphorylation in PIKE
/
WAT also provides a possible explanation for the defec-
tive adipogenesis observed, because prolonged AICAR-
induced AMPK activation inhibits adipocyte differentiation
by diminishing PPAR and C/EBP expressions (33,34).
Furthermore, agonist-activated AMPK potentiates the
insulin-stimulated glucose uptake by activating IRS-1
(35,36), which may explain the enhanced PI 3-kinase
and Akt activities in the muscle and WAT of PIKE
/
mice.
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FIG. 5. Enhanced lipid oxidation in PIKE
/ mice. A: Serum triglyceride level of wild-type (/) and knockout (/) mice (8–9 months old) that
have been fed with chow or HFD for 20 weeks. Results were expressed as mean  SEM (n  4; ***P < 0.001 vs. the same genotype; one-way
ANOVA). B: Hematoxylin-eosin (H&E) (upper panel) and oil red O (lower panel) staining of liver sections collected from wild-type (/) and
knockout (/) mice (8–9 months old) that have been fed with HFD for 20 weeks. Scale bar represents 50 m. Representative result of three
mice from each genotype is shown. C: Spontaneous activity of wild-type (/) and PIKE knockout (/) mice fed with chow or HFD for 14 weeks.
Results were expressed as mean  SEM (n  7; *P < 0.05, ***P < 0.001 vs. the same diet). D: Oxygen consumption (top panel), CO2 release
(middle panel), and respiratory exchange ratio (bottom panel) in wild-type (solid bar) and knockout (open bar) mice fed with chow and HFD
for 20 weeks (n  4). Results were expressed as mean  SEM (**P < 0.01, ***P < 0.001 vs. the same diet; a: P < 0.05, c: P < 0.001 vs. the same
genotype, one-way ANOVA, n  4). E: Analysis of ACC and AMPK phosphorylation in wild-type (/) and knockout (/) mice (8–9 months old)
that have been fed with chow or HFD for 20 weeks. Extracts of inguinal WAT, BAT, and muscle were prepared and immunoblotted with
phosphor–Thr
172-AMPK, phosphor–Ser
79-ACC, total AMPK, and ACC antibodies. F: Elevated fatty acid oxidation in PIKE
/ muscle cells. Rate
of
3H-palmitate oxidation was measured in cultured skeletal muscle cells and hepatocytes isolated from wild-type (/) and PIKE knockout
(/) mice. Results were expressed as mean  SEM (*P < 0.05, one-way ANOVA, n  5). (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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phosphorylation. Next, we sought to clarify the role of
PIKE-A in modulating AMPK phosphorylation. Fyn knock-
out (Fyn
/) mice are lipodystrophic with enhanced
AMPK activity in muscle and WAT (37). These metabolic
characteristics highly resemble the phenotypes of
PIKE
/ mice. Given that PIKE-A is a substrate of Fyn
(38) and Fyn interacts with IRS-1 in an insulin-dependent
manner (39), we hypothesized that PIKE-A may form a
complex with Fyn and insulin receptor upon insulin stim-
ulation, which is essential for insulin to suppress AMPK
activity (40,41). In HEK293 cells, PIKE-A associated with
insulin receptor through its NH2-terminal (1–72 amino
acids) (Fig. 6A and B), in which their interaction could be
enhanced by insulin stimulation (Fig. 6C, ﬁrst panel).
However, this interaction was abolished when the Fyn
phosphorylation site (Tyr682 and Tyr774) in PIKE-A
(PIKE-A YY) was mutated (Fig. 6C, ﬁrst panel), suggesting
Fyn phosphorylation is critical to the formation of PIKE-
A/insulin receptor complex. The kinetics of insulin recep-
tor/PIKE-A complex formation inversely correlated with
the phosphorylation of AMPK (Fig. 6D, ﬁrst and sixth
panels). Remarkably, neither Thr
172 nor Ser
485/Ser
491 phos-
phorylation (42) was altered by insulin in GST-PIKE-A
YY–transfected cells (Fig. 4D, sixth and seventh panels),
suggesting that PIKE-A binding to insulin receptor is
critical to mediate the inhibitory action of insulin on
AMPK phosphorylation. On the other hand, Akt phosphor-
ylation was not affected in either wild-type PIKE-A or
PIKE-A YY cells in response to insulin (Fig. 6D, fourth
panel). The formation of PIKE/insulin receptor/Fyn com-
plex was further demonstrated in muscle tissue. In vivo
insulin injection in wild-type mice enhanced the formation
of PIKE-A/insulin receptor complex, which was substan-
tially reduced in Fyn
/ tissue (Fig. 4G, ﬁrst panel). This
complex was not detected in PIKE-null tissues (Fig. 6E,
ﬁrst panel). Our immunoprecipitation results also con-
ﬁrmed that the association of Fyn and insulin receptor in
muscle is insulin dependent (Fig. 6E, second panel).
Furthermore, the formation of Fyn/insulin receptor com-
plex was not affected in PIKE-null tissues, suggesting that
PIKE-A is not essential for their interaction (Fig. 6E,
second panel). Thus, the interaction between PIKE-A and
insulin receptor is important for insulin to suppress AMPK
phosphorylation, which provides a possible explanation to
the enhanced AMPK phosphorylation in PIKE
/ WAT
and muscle.
DISCUSSION
One of the major ﬁndings in the current report is that
PIKE-A is critical for adipocyte differentiation. Several
lines of evidence support the role of PIKE-A in terminal
adipocyte differentiation instead of preadipocyte forma-
tion. First, the mature adipocyte marker aP2 is signiﬁ-
cantly decreased during in vitro adipocyte differentiation
in PIKE
/ MEFs, indicating PIKE-A is important for
adipocyte differentiation (Fig. 3B and C). Second, PIKE-A
expression is increased in fat tissue development of HFD-
fed and ob/ob mice, which highlights its function in the
process (Fig. 2H). Lastly, HFD induced comparable prea-
dipocyte marker Pref-1 expression in both wild-type and
PIKE
/ mice, indicating that formation of new adipo-
cytes is normal in PIKE-null adipose tissue (Fig. 3A).
Interestingly, we found a small portion of PIKE
/ MEFs
was able to differentiate into mature adipocytes (Fig. 3B),
and quantitative analysis revealed a small but statistically
signiﬁcant increment of lipid accumulation in PIKE
/
MEFs (Fig. 3C). This result indicates that a PIKE-A–
independent mechanism is responsible for some adipocyte
differentiation, which also accounts for the existence but
not completely the absence of adipose tissue in PIKE
/
mice.
Ectopic lipid storage due to adipocyte differentiation
defect is associated with hyperlipidemia and liver steatosis
(43). However, we could not detect these pathologic
conditions in PIKE
/ mice (Fig. 5A and B). It is thus
reasonable to predict that the lipid spillover from adipo-
cyte is metabolized in mutant animals. Our results that
PIKE-null fat and muscle have signiﬁcantly elevated AMPK
and ACC phosphorylation suggest an elevated 	-oxidation
in these tissues (Fig. 5E), which is further supported by
the enhanced fatty acid oxidation rate in the in vitro assay
(Fig. 5F) and the low respiratory exchange ratio values
(Fig. 5D). AMPK has been viewed as a fuel sensor for
glucose and lipid metabolism. Once activated, AMPK
initiates a concomitant inhibition of energy-consuming
biosynthetic pathways and activation of ATP-producing
pathways such as fatty oxidation in mitochondria (44). As
a result, most of the lipids absorbed in PIKE
/ mice are
oxidized as the energy source, which accounts for the lean
phenotype during the HFD treatment.
The uplifted phosphorylation of AMPK and its down-
stream substrate ACC in PIKE-null muscle and adipose
tissues indicates that PIKE-A negatively regulates the
activities of these enzymes. This notion is further sup-
ported by the fact that PIKE-A is critical for insulin to
inhibit AMPK phosphorylation in 293 cells (Fig. 6D). This
upregulation of AMPK activity in PIKE
/ muscle and fat
also provides a possible mechanism accounting for the
elevated systemic insulin sensitivity, as AMPK and insulin
signaling are intimately connected. Agonist-induced AMPK
activation increases the glucose uptake in muscle (45). It
also potentiates the insulin-stimulated glucose uptake by
activating IRS-1 (35,36). A similar observation was made in
cells were cotransfected with His-IR and GST alone, GST-tagged wild-type PIKE-A (WT), or Tyr682, 774F (YY) mutant. The GST proteins were
pulled down by glutathione beads and the associated insulin receptor was examined using anti–insulin receptor antibody (ﬁrst panel).
Expression of His-IR (second panel) and various GST-tagged proteins (third and fourth panels) was detected. Phosphorylation of Akt (Ser
473)
was also examined to verify insulin action (ﬁfth panel). Total Akt expression was checked as an indication of equal loading (sixth panel). D:
Mutation of Fyn phosphorylation site impairs insulin-suppressed AMPK phosphorylation. HEK293 cells were ﬁrst transfected with GST-tagged
wild-type PIKE-A (WT) or Tyr682, 774F mutant (YY). After serum starvation for 24 h, the cells were stimulated with 100 nmol/l insulin for
different time intervals. The PIKE proteins were pulled down by glutathione beads, and the associated insulin receptor was detected using
anti–insulin receptor antibody (ﬁrst panel). The phosphorylation of Akt (Ser
473; fourth panel), AMPK (Thr
172; sixth panel), and AMPK1
(Ser
485)/AMPK2 (Ser
491; seventh panel) was determined using speciﬁc antibodies. Expression of His-IR (second panel) and GST-PIKE-A (third
panel) was veriﬁed. The amount of Akt (ﬁfth panel) and AMPK (eighth panel) was detected to show equal loading. E: Insulin enhances PIKE-A
and insulin receptor interaction in muscle. Overnight-fasted wild-type (/), Fyn knockout (Fyn
/), and PIKE knockout (PIKE
/) mice (3–4
months old) were injected with saline () or 5 units human insulin () through the inferior vena cava for 5 min. The muscles were then collected
and homogenized, and the PIKE-A was immunoprecipitated using anti-PIKE antibody. The associated insulin receptor was detected using
anti–insulin receptor antibody (ﬁrst panel). The interaction of Fyn and insulin receptor was also examined by immunoprecipitation using
anti-Fyn antibody (second panel). Phosphorylation of insulin receptor was examined as an indication of insulin stimulation (third panel). Total
insulin receptor was also detected to indicate loading (fourth panel).
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agonist AICAR enhanced basal glucose uptake by increas-
ing GLUT4 translocation (46). Long-term activation of
AMPK in mice increases the systemic insulin sensitivity
and protects animals from HFD-induced obesity and dia-
betes (34,47), which is in agreement with our observations
in PIKE
/ mice. It is noteworthy that the alleviated
insulin resistance in PIKE
/ mice after HFD treatment
may be a result of reduced inﬂammation. Because reduced
circulating TNF- could improve insulin sensitivity and
increase AMPK activity (48,49), the low blood TNF- in
PIKE
/ mice (Fig. 2G) may also contribute signiﬁcantly
to improve the diet-induced insulin resistance.
Because the whole-body–knockout mice were used in
the present study, we cannot exclude the possibility that
deletion of PIKE-A in the brain causes a central effect to
modify whole-body activity and metabolism. Because
brain is the major site to control appetite and body weight
(50), where PIKE is highly expressed (Fig. 1D), it is
reasonable to suspect that reduced food intake (Fig. 2B)
and elevated physical activity (Fig. 5C)i nPIKE
/ mice
are the primary causes of lean phenotype during HFD
treatment. However, our data strongly support that periph-
eral ablation of PIKE-A does play a role in preventing
obesity development. First, the feeding behavior is com-
parable between wild-type and PIKE
/ mice fed a chow
diet, when lipoatrophy is already obvious. Second, in-
duced differentiation in PIKE
/ MEFs is greatly impaired
(Fig. 3B), suggesting ablation of PIKE per se in MEFs is
adequate to suppress adipogenesis. Third, PIKE-A inter-
acts with the insulin receptor in a Fyn-dependent manner,
which is essential for insulin-induced AMPK phosphoryla-
tion in muscle (Fig. 6D). Deletion of PIKE in muscle,
therefore, would enhance the AMPK phosphorylation and
lipid oxidation (Fig. 5E and F). Lastly, isolated PIKE
/
WAT and muscle, in which the metabolic inﬂuence by the
brain is eliminated, have higher
3H-2-deoxyglucose uptake
when stimulated by insulin (Fig. 4F).
Our data also suggest that the function of PIKE-A is not
restricted to enhance Akt activity alone. We have demon-
strated that PIKE-A physically interacts with the insulin
receptor, which is important for insulin to suppress AMPK
phosphorylation. Our data also provide a novel mechanis-
tic insight into the phenotypes observed in Fyn
/ mice
(37), as PIKE-A/insulin receptor association is Fyn depen-
dent. Conceivably, PIKE-A is a downstream target of Fyn
that inhibits the activity of AMPK during obesity develop-
ment. Thus, PIKE-A may represent an additional regula-
tory point, in addition to Akt, for insulin to suppress AMPK
phosphorylation.
In all, our results uncover the novel physiological func-
tions of PIKE-A, which plays important roles in obesity
development and the accompanied insulin resistance by
regulating AMPK activities negatively. Consequently, less
fat is deposited and the associated insulin resistance is
ameliorated. Therefore, PIKE-A may represent a potential
therapeutic target for obesity and the adjunct insulin
resistance.
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